Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	15.42B
Revenue (ttm)	1.83B
Net Income (ttm)	490.68M
Shares Out	316.05M
EPS (ttm)	1.59
PE Ratio	30.72
Forward PE	24.24
Dividend	0.64 (1.30%)
Ex-Dividend Date	Jun 12, 2025

Volume	12,958,226
Average Volume	16,886,823
Open	50.03
Previous Close	49.31
Day's Range	47.40 - 50.86
52-Week Range	29.86 - 58.21
Beta	0.53
RSI	75.33
Earnings Date	Aug 21, 2025

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers APIs, including peptides, small molecules, and oligonucleotides; and intermediate products, such as fulvestrant, oseltamivir, and other intermediates. It also provides CRDMO/CMO services. The company was founded in 2009 and is headquartered in Hangzhou City, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 2,028
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2024, SHA:688076's revenue was 1.62 billion, an increase of 57.21% compared to the previous year's 1.03 billion. Earnings were 404.39 million, an increase of 148.19%.